CorMedix (CRMD) Cash from Investing Activities (2010 - 2025)
CorMedix (CRMD) posted Cash from Investing Activities of $3.3 million for Q4 2025, up 101.13% sequentially from -$291.3 million in Q3 2025, and up 1185.0% YoY from $256578.5 in Q4 2024.
CorMedix (CRMD) Cash from Investing Activities (2010 - 2025) Analysis & Trends
CorMedix has reported Cash from Investing Activities for 12 years, with the latest figure at $3.3 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 1185.0% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$308.4 million (down 1552.73% YoY) and the FY2025 annual result came in at -$308.4 million, down 1552.73% from the prior year.
- Cash from Investing Activities improved to $3.3 million in Q4 2025 per CRMD's latest filing, from -$291.3 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $8.9 million in Q1 2024 and troughed at -$291.3 million in Q3 2025.
- A 5-year average of -$15.9 million and a median of -$256074.5 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 32222.08% in 2023, then tumbled 4708.5% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$7.1 million in 2021, then surged by 99.97% to -$1861.0 in 2022, then soared by 32222.08% to $597792.0 in 2023, then sank by 150.83% to -$303874.0 in 2024, then soared by 1185.0% to $3.3 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $3.3 million, -$291.3 million, and -$20.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.30 Mn |
| Dec 31, 2025 | 3.30 Mn |
| Sep 30, 2025 | -291.32 Mn |
| Sep 30, 2025 | -291.32 Mn |
| Jun 30, 2025 | -20.21 Mn |
| Jun 30, 2025 | -20.21 Mn |
| Mar 31, 2025 | -194,820.00 |
| Mar 31, 2025 | -194,820.00 |
| Dec 31, 2024 | -303,874.00 |
| Dec 31, 2024 | -303,874.00 |
| Sep 30, 2024 | 6.32 Mn |
| Sep 30, 2024 | 6.32 Mn |
| Jun 30, 2024 | 6.27 Mn |
| Jun 30, 2024 | 6.27 Mn |
| Mar 31, 2024 | 8.94 Mn |
| Mar 31, 2024 | 8.94 Mn |
| Dec 31, 2023 | 597,792.00 |
| Dec 31, 2023 | 597,792.00 |
| Sep 30, 2023 | -586,866.00 |
| Sep 30, 2023 | -586,866.00 |